Assessing the clinical severity and treating peri-implantitis surrounding dental implants in patients who recovered from COVID-19

Phase 3

Conditions: Health Condition 1: T857- Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts

Registration Number: CTRI/2024/04/065969

Lead Sponsor: Council of Science and Technology U P

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Post covid-19 healthy subjects will be recruited who have SPO2, Pulse rate, Blood pressure within standard limits.

Ability to understand the procedure and provide informed consent assessed by decision making capacity and approaches before being included in the study.

Diagnosis of peri-implantitis based on the soft tissue around the implant showing obvious inflammatory symptoms, bone loss revealed by X-ray examination and probable haemorrhage and suppuration.

At least 2 implant site with periodontal PD =4- 6 mm.

Plaque Index around the implant = 2 points

Visible bleeding around the implant after probing.

CAL = 3 mm.

Exclusion Criteria

Current smoking habit with moderate or heavy smoking (more than 10 cigarettes per day) or chewing tobacco.

History of drug abuse or alcoholism within the past 5 years

Severe bruxism or clenching habit.

Significant untreated periodontal disease (grade III or IV), caries, or clinical or radiographic signs of infection within two adjacent tooth positions of implant area.

History of systemic disease that precludes standard dental implant therapy.

Past history of implant repair and failure over past 6 months.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Clinical evaluation of Peri-implant plaque index (PI), BOP, PPD, CAL. <br/ ><br>2. Radiographically evaluation of Marginal bone loss. <br/ ><br>3. Evaluation of OPG levels in Peri-implant sulcular fluid (PISF).Timepoint: Upto 2 years

Secondary Outcome Measures